115 related articles for article (PubMed ID: 12115502)
1. CHC1-L, a candidate gene for prostate carcinogenesis at 13q14.2, is frequently affected by loss of heterozygosity and underexpressed in human prostate cancer.
Latil A; Morant P; Fournier G; Mangin P; Berthon P; Cussenot O
Int J Cancer; 2002 Jun; 99(5):689-96. PubMed ID: 12115502
[TBL] [Abstract][Full Text] [Related]
2. Extensive analysis of the 13q14 region in human prostate tumors: DNA analysis and quantitative expression of genes lying in the interval of deletion.
Latil A; Chêne L; Mangin P; Fournier G; Berthon P; Cussenot O
Prostate; 2003 Sep; 57(1):39-50. PubMed ID: 12886522
[TBL] [Abstract][Full Text] [Related]
3. An 800-kb region of deletion at 13q14 in human prostate and other carcinomas.
Chen C; Frierson HF; Haggerty PF; Theodorescu D; Gregory CW; Dong JT
Genomics; 2001 Oct; 77(3):135-44. PubMed ID: 11597138
[TBL] [Abstract][Full Text] [Related]
4. Expression mapping at 12p12-13 in advanced prostate carcinoma.
Kibel AS; Huagen J; Guo C; Isaacs WB; Yan Y; Pienta KJ; Goodfellow PJ
Int J Cancer; 2004 May; 109(5):668-72. PubMed ID: 14999772
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer.
Bièche I; Lidereau R
Mol Carcinog; 2000 Nov; 29(3):151-8. PubMed ID: 11108660
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer.
Dong JT; Boyd JC; Frierson HF
Prostate; 2001 Nov; 49(3):166-71. PubMed ID: 11746261
[TBL] [Abstract][Full Text] [Related]
7. cDNA cloning, gene characterization and 13q14.3 chromosomal assignment of CHC1-L, a chromosome condensation regulator-like guanine nucleotide exchange factor.
Devilder MC; Cadoret E; Chérel M; Moreau I; Rondeau G; Bézieau S; Moisan JP
Genomics; 1998 Nov; 54(1):99-106. PubMed ID: 9806834
[TBL] [Abstract][Full Text] [Related]
8. Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer.
Hyytinen ER; Frierson HF; Boyd JC; Chung LW; Dong JT
Genes Chromosomes Cancer; 1999 Jun; 25(2):108-14. PubMed ID: 10337994
[TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity at chromosome arm 13q and RB1 status in human prostate cancer.
Latil A; Bièche I; Pesche S; Volant A; Valèri A; Fournier G; Cussenot O; Lidereau R
Hum Pathol; 1999 Jul; 30(7):809-15. PubMed ID: 10414500
[TBL] [Abstract][Full Text] [Related]
10. Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer.
Fromont G; Valeri A; Cher M; Pontes JE; Vallancien G; Validire P; Latil A; Cussenot O
Prostate; 2005 Dec; 65(4):341-6. PubMed ID: 16015610
[TBL] [Abstract][Full Text] [Related]
11. Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene.
Chêne L; Giroud C; Desgrandchamps F; Boccon-Gibod L; Cussenot O; Berthon P; Latil A
Int J Cancer; 2004 Sep; 111(5):798-804. PubMed ID: 15252854
[TBL] [Abstract][Full Text] [Related]
12. Allelotyping analysis at chromosome 13q of high-grade prostatic intraepithelial neoplasia and clinically insignificant and significant prostate cancers.
Lu W; Takahashi H; Furusato M; Maekawa S; Nakano M; Meng C; Kikuchi Y; Sudo A; Hano H
Prostate; 2006 Mar; 66(4):405-12. PubMed ID: 16302266
[TBL] [Abstract][Full Text] [Related]
13. Limiting the location of a putative human prostate cancer tumor suppressor gene at chromosome 13q14.3.
Yin Z; Spitz MR; Babaian RJ; Strom SS; Troncoso P; Kagan J
Oncogene; 1999 Dec; 18(52):7576-83. PubMed ID: 10602517
[TBL] [Abstract][Full Text] [Related]
14. Identification of a I-cM region of common deletion on 13q14 associated with human prostate cancer.
Ueda T; Emi M; Suzuki H; Komiya A; Akakura K; Ichikawa T; Watanabe M; Shiraishi T; Masai M; Igarashi T; Ito H
Genes Chromosomes Cancer; 1999 Mar; 24(3):183-90. PubMed ID: 10451697
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions.
Latil A; Cussenot O; Fournier G; Driouch K; Lidereau R
Cancer Res; 1997 Mar; 57(6):1058-62. PubMed ID: 9067271
[TBL] [Abstract][Full Text] [Related]
16. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
17. Is there any association between nek3 and cancers with frequent 13q14 deletion?
Hernández M; Almeida TA
Cancer Invest; 2006 Nov; 24(7):682-8. PubMed ID: 17118778
[TBL] [Abstract][Full Text] [Related]
18. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity at 7q31.1 and 12p13-12 in advanced prostate cancer.
Kawana Y; Ichikawa T; Suzuki H; Ueda T; Komiya A; Ichikawa Y; Furuya Y; Akakura K; Igarashi T; Ito H
Prostate; 2002 Sep; 53(1):60-4. PubMed ID: 12210480
[TBL] [Abstract][Full Text] [Related]
20. Distinct regions of allelic loss on 13q in prostate cancer.
Cooney KA; Wetzel JC; Merajver SD; Macoska JA; Singleton TP; Wojno KJ
Cancer Res; 1996 Mar; 56(5):1142-5. PubMed ID: 8640774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
